Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.

2.

'Next Berlin Patient' Adds to Small but Growing Number of People Cured of HIV

3.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

4.

Q&A: Odds of surviving cancer drop drastically when credit score dips

5.

November 2023, Medical Bulletin 04/.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot